%0 Journal Article %A KAZUKI SONE %A TETSUYA OGURI %A KEIMA ITO %A YUKI KITAMURA %A YOSHITSUGU INOUE %A AKIRA TAKEUCHI %A SATOSHI FUKUDA %A OSAMU TAKAKUWA %A KEN MAENO %A TAKAMITSU ASANO %A YOSHIHIRO KANEMITSU %A HIROTSUGU OHKUBO %A MASAYA TAKEMURA %A YUTAKA ITO %A AKIO NIIMI %T Predictive Role of CYFRA21-1 and CEA for Subsequent Docetaxel in Non-small Cell Lung Cancer Patients %D 2017 %J Anticancer Research %P 5125-5131 %V 37 %N 9 %X Background/Aim: The aim of the present study was to determine the clinical value of tumor marker levels for previously treated NSCLC patients. Patients and Methods: We retrospectively screened 113 previously treated patients with advanced NSCLC who were treated with docetaxel monotherapy regarding the pretreatment serum level of cytokeratin 19 fragment (CYFRA21-1) and carcinoembryonic antigen (CEA). Results: The thirty-two patients with normal CYFRA21-1 levels and high CEA levels had a significantly higher response rate than the other 81 patients (25% vs. 8.6%, p=0.031). The former group showed statistically longer progression-free survival (PFS) and overall survival (OS) than the latter group (median PFS, 180 vs. 59 days, p<0.001; median OS, 579 vs. 255 days, p=0.002). In multivariate analysis, tumor marker levels had a significant impact on PFS and OS. Conclusion: Combination of the two tumor markers is a predictive and prognostic marker of docetaxel monotherapy for previously treated NSCLC patients. %U https://ar.iiarjournals.org/content/anticanres/37/9/5125.full.pdf